-
公开(公告)号:US10214554B2
公开(公告)日:2019-02-26
申请号:US15427674
申请日:2017-02-08
发明人: John Y. L. Chung , Amude Kassim , John Limanto , Michael Shevlin , Peter E. Maligres , Daniel A. DiRocco , James F. Dropinski , Rose Mathew , Yi Ning Ji Chen , Edward C. Sherer , Mikhail Reibarkh , Artis Klapars , Alan Hyde , Susan L. Zultanski , Aaron Moment , Bryon Simmons , Tyler A. Davis , Timothy James Wright , Ralph Calabria , Louis charles Campeau
IPC分类号: C07H19/00 , C07H19/048 , C07H19/10 , C07H19/06 , C07H19/24 , C07D487/04
摘要: The present invention is directed to a process for making Chloro-Substituted Nucleoside Phosphoramidate Compounds of formula (I): which are useful for the treatment and prophylaxis of HCV infection. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).
-
公开(公告)号:US10251903B2
公开(公告)日:2019-04-09
申请号:US15519846
申请日:2015-10-20
申请人: MERCK SHARP & DOHME CORP. , IDENIX Pharmaceuticals LLC , Bryon L. Simmons , Kevin R. Campos , Artis Klapars , Alistair J. Stewart , Benjamin A. Mayes , Peter E. Maligres , Alan Hyde , Steven Mark Silverman , Yong-Li Zhong , Adel M. Moussa , Kenneth Baker , Kara Van Valkenburg
发明人: Bryon L. Simmons , Kevin R. Campos , Artis Klapars , Alistair J. Stewart , Benjamin A. Mayes , Peter E. Maligres , Alan Hyde , Steven Mark Silverman , Yong-Li Zhong , Adel M. Moussa , Kenneth Baker , Kara Van Valkenburg
IPC分类号: C07H19/10 , A61K31/7052 , C07H1/00 , C08K3/08
摘要: The present invention is directed to a process for making Nucleoside Phosphoramidate Compounds of formula (I): which are useful for the treatment and prophylaxis of HCV infection. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).
-
公开(公告)号:US10308633B2
公开(公告)日:2019-06-04
申请号:US15761754
申请日:2016-09-26
发明人: Qinghao Chen , Shane W. Krska , Lushi Tan , Peter E. Maligres , Jeremy Scott , Carl Baxter , Gavin William Stewart , Andrew Gibb
IPC分类号: C07D239/70 , C07D401/06 , C07D401/10 , A61K31/517 , A61P25/28
摘要: This invention provides novel processes for the preparation of compounds such as 3-[(1S,2S)-2-hydroxycyclohexyl]-6-[(6-methylpyridin-3-yl)methyl]benzo[h]-quinazolin-4(3H)-one, salts and derivatives thereof. The compounds synthesized by the processes of the invention are useful for treating Alzheimer's disease and other diseases (e.g., cognitive impairment, schizophrenia, pain disorders, and sleep disorders) mediated by the muscarinic M1 receptor.
-
公开(公告)号:US20180265493A1
公开(公告)日:2018-09-20
申请号:US15761754
申请日:2016-09-26
发明人: Qinghao Chen , Shane W. Krska , Lushi Tan , Peter E. Maligres , Jeremy Scott , Carl Baxter , Gavin William Stewart , Andrew Gibb
IPC分类号: C07D401/06
CPC分类号: C07D401/06 , A61K31/517
摘要: This invention provides novel processes for the preparation of compounds such as 3-[(1S,2S)-2-hydroxycyclohexyl]-6-[(6-methylpyridin-3-yl)methyl]benzo[h]-quinazolin-4(3H)-one, salts and derivatives thereof. The compounds synthesized by the processes of the invention are useful for treating Alzheimer's disease and other diseases (e.g., cognitive impairment, schizophrenia, pain disorders, and sleep disorders) mediated by the muscarinic M1 receptor.
-
公开(公告)号:US09145348B2
公开(公告)日:2015-09-29
申请号:US14355105
申请日:2012-10-26
IPC分类号: C07D263/20 , C07C41/18 , C07C41/30 , A01N43/76 , A61K31/421
CPC分类号: C07C41/18 , C07C41/30 , C07D263/20 , C07C43/23 , C07C43/225
摘要: An efficient process is disclosed for producing the compound of formula I, which is the CETP inhibitor anacetrapib, which raises HDL-cholesterol and reduces LDL-cholesterol in human patients and may be effective for treating or reducing the risk of developing atherosclerosis:
摘要翻译: 公开了一种有效的方法,用于生产式I化合物,其为CETP抑制剂anacetrapib,其提高人类患者的HDL-胆固醇并降低LDL-胆固醇,并且可有效治疗或降低发展动脉粥样硬化的风险:
-
公开(公告)号:US20140303380A1
公开(公告)日:2014-10-09
申请号:US14355105
申请日:2012-10-26
IPC分类号: C07C41/18 , C07D263/20
CPC分类号: C07C41/18 , C07C41/30 , C07D263/20 , C07C43/23 , C07C43/225
摘要: An efficient process is disclosed for producing the compound of formula I, which is the CETP inhibitor anacetrapib, which raises HDL-cholesterol and reduces LDL-cholesterol in human patients and may be effective for treating or reducing the risk of developing atherosclerosis:
摘要翻译: 公开了一种有效的方法,用于生产式I化合物,其为CETP抑制剂anacetrapib,其提高人类患者的HDL-胆固醇并降低LDL-胆固醇,并且可有效治疗或降低发展动脉粥样硬化的风险:
-
公开(公告)号:US09725464B2
公开(公告)日:2017-08-08
申请号:US15032552
申请日:2014-10-24
发明人: Ian Mangion , Cheng-yi Chen , Ingyu Jeon , Yonggang Chen , Hongmei Li , Hoa N. Nguyen , Peter E. Maligres , Artis Klapars , Ilia Zavialov , Nobuyoshi Yasuda
IPC分类号: C07D498/04 , C07D403/04 , C07C215/50 , C07F5/02 , C07C213/02
CPC分类号: C07D498/04 , C07C213/02 , C07C215/50 , C07D403/04 , C07F5/025
摘要: The present invention is directed to a process for preparing Tetracyclic Heterocycle Compounds of formula (I): which are useful as HCV NS5A inhibitors. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).
-
公开(公告)号:US20160257698A1
公开(公告)日:2016-09-08
申请号:US15032552
申请日:2014-10-24
发明人: Ian Mangion , Cheng-yi Chen , Ingyu Jeon , Yonggang Chen , Hongmei Li , Hoa N. Nguyen , Peter E. Maligres , Artis Klapars , Ilia Zavialov , Nobuyoshi Yasuda
IPC分类号: C07D498/04 , C07D403/04 , C07C213/02
CPC分类号: C07D498/04 , C07C213/02 , C07C215/50 , C07D403/04 , C07F5/025
摘要: The present invention is directed to a process for preparing Tetracyclic Heterocycle Compounds of formula (I): which are useful as HCV NS5A inhibitors. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).
摘要翻译: 本发明涉及制备式(I)的四环杂环化合物的方法:其可用作HCV NS5A抑制剂。 本发明还涉及可用作制备式(I)化合物的合成中间体的化合物。
-
-
-
-
-
-
-